Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN.M)
Israel · Delayed Price · Currency is ILS · Price in ILA 120,000
+27,800 (30.15%)
At close: Oct 21, 2026
TLV:TKUN.M Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue | 1.05 | 9.1 | 34.95 | 44.23 | 49.3 | 37.03 |
Revenue Growth | -95.35% | -73.96% | -20.97% | -10.28% | 33.13% | 70.97% |
Cost of Revenue | 1.26 | 7.35 | 29.53 | 32.7 | 31.19 | 29.38 |
Gross Profit | -0.21 | 1.75 | 5.43 | 11.53 | 18.11 | 7.65 |
Selling, General & Admin | 6.77 | 10.47 | 12.62 | 22.82 | 23.95 | 27.66 |
Research & Development | - | - | 0.83 | 3.89 | 5.16 | 7.2 |
Other Operating Expenses | -11.44 | -1.62 | -0.12 | -0.81 | -0.33 | 0.85 |
Operating Expenses | -4.33 | 9.72 | 19.98 | 39.19 | 44.45 | 50.7 |
Operating Income | 4.12 | -7.97 | -14.55 | -27.66 | -26.34 | -43.05 |
Interest Expense | -0.79 | -1.12 | -1.88 | -2.3 | -1.77 | -1.28 |
Interest & Investment Income | 0.04 | 0.04 | - | 0.13 | 0.09 | 0.01 |
Earnings From Equity Investments | - | - | - | -0.38 | - | - |
EBT Excluding Unusual Items | 3.37 | -9.05 | -16.44 | -30.21 | -28.02 | -44.32 |
Impairment of Goodwill | -11.27 | -11.27 | -22.34 | -59.63 | -17.57 | - |
Gain (Loss) on Sale of Investments | - | - | -4.73 | -0.43 | 1.93 | - |
Gain (Loss) on Sale of Assets | -0.84 | -0.84 | - | -0.17 | - | - |
Asset Writedown | - | - | - | - | -15.27 | - |
Other Unusual Items | 5.34 | 5.34 | 3.4 | -3.56 | 9.79 | 10.29 |
Pretax Income | -3.4 | -15.82 | -40.1 | -93.99 | -49.14 | -34.03 |
Income Tax Expense | - | - | - | 0.03 | 0.01 | - |
Earnings From Continuing Operations | -3.4 | -15.82 | -40.1 | -94.02 | -49.15 | -34.03 |
Minority Interest in Earnings | -0.04 | -0.03 | 0 | 5.13 | 0.91 | 1.38 |
Net Income | -3.44 | -15.85 | -40.1 | -88.89 | -48.24 | -32.65 |
Net Income to Common | -3.44 | -15.85 | -40.1 | -88.89 | -48.24 | -32.65 |
Net Income Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 0.64 | 2.01 | -3.78 | -4.12 | -23.2 | -33.49 |
Gross Margin | -19.94% | 19.25% | 15.52% | 26.06% | 36.73% | 20.66% |
Operating Margin | 391.64% | -87.53% | -41.63% | -62.53% | -53.44% | -116.25% |
Profit Margin | -326.59% | -174.17% | -114.73% | -200.97% | -97.85% | -88.17% |
Free Cash Flow Margin | 60.87% | 22.08% | -10.82% | -9.31% | -47.07% | -90.43% |
EBITDA | 3.6 | 3.96 | 14.22 | 29.08 | 9.2 | -25.89 |
EBITDA Margin | 341.79% | 43.52% | 40.69% | 65.74% | 18.66% | -69.92% |
D&A For EBITDA | -0.53 | 11.93 | 28.77 | 56.73 | 35.54 | 17.15 |
EBIT | 4.12 | -7.97 | -14.55 | -27.66 | -26.34 | -43.05 |
EBIT Margin | 391.64% | -87.53% | -41.63% | -62.53% | -53.44% | -116.25% |